Mark Thomas

1.4k total citations
38 papers, 566 citations indexed

About

Mark Thomas is a scholar working on Nephrology, Physiology and Surgery. According to data from OpenAlex, Mark Thomas has authored 38 papers receiving a total of 566 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Nephrology, 8 papers in Physiology and 6 papers in Surgery. Recurrent topics in Mark Thomas's work include Lysosomal Storage Disorders Research (7 papers), Renal Diseases and Glomerulopathies (6 papers) and Multiple Myeloma Research and Treatments (3 papers). Mark Thomas is often cited by papers focused on Lysosomal Storage Disorders Research (7 papers), Renal Diseases and Glomerulopathies (6 papers) and Multiple Myeloma Research and Treatments (3 papers). Mark Thomas collaborates with scholars based in Australia, United States and United Kingdom. Mark Thomas's co-authors include L.S. Ibels, Kate Brameld, Ashley Irish, S. Herrmann, Gursharan Dogra, Gerald F. Watts, C. D’Arcy J. Holman, A. Bass, Ian Rouse and A. G. R. Sheil and has published in prestigious journals such as The Lancet, PLoS ONE and Kidney International.

In The Last Decade

Mark Thomas

35 papers receiving 548 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Thomas Australia 14 143 126 97 95 72 38 566
Mohammad Kamgar United States 12 157 1.1× 62 0.5× 85 0.9× 77 0.8× 61 0.8× 31 647
Sônia K. Nishida Brazil 17 254 1.8× 82 0.7× 85 0.9× 44 0.5× 65 0.9× 42 669
Max Plischke Austria 9 209 1.5× 82 0.7× 36 0.4× 49 0.5× 58 0.8× 17 579
Miyeun Han South Korea 16 263 1.8× 146 1.2× 35 0.4× 81 0.9× 80 1.1× 73 720
Maria Faria Portugal 17 303 2.1× 116 0.9× 73 0.8× 74 0.8× 76 1.1× 80 852
Taner Baştürk Türkiye 15 397 2.8× 119 0.9× 53 0.5× 68 0.7× 79 1.1× 75 717
David Tovbin Israel 15 144 1.0× 64 0.5× 60 0.6× 55 0.6× 95 1.3× 41 622
Mustafa Sevinç Türkiye 13 231 1.6× 108 0.9× 33 0.3× 74 0.8× 56 0.8× 49 476
Elbis Ahbap Türkiye 13 298 2.1× 95 0.8× 36 0.4× 55 0.6× 58 0.8× 53 511
Rajni Sharma India 14 133 0.9× 293 2.3× 55 0.6× 106 1.1× 55 0.8× 84 824

Countries citing papers authored by Mark Thomas

Since Specialization
Citations

This map shows the geographic impact of Mark Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Thomas more than expected).

Fields of papers citing papers by Mark Thomas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Thomas. The network helps show where Mark Thomas may publish in the future.

Co-authorship network of co-authors of Mark Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Thomas. A scholar is included among the top collaborators of Mark Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Thomas. Mark Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Ping, Hongxia Lin, Yongjun Xue, et al.. (2025). A population pharmacokinetic analysis to evaluate the impact of renal impairment on the pharmacokinetics of iberdomide. Journal of Pharmaceutical Sciences. 114(2). 1315–1325.
2.
Nicholls, Kathy, Charles Denaro, Michel Tchan, et al.. (2024). Fabry‐specific treatment in Australia: time to align eligibility criteria with international best practices. Internal Medicine Journal. 54(6). 882–890.
3.
Chen, Yizhe, D.J. Wyatt, Massimo Attanasio, et al.. (2023). Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults. Cancer Chemotherapy and Pharmacology. 93(4). 307–317. 2 indexed citations
4.
Hughes, Derralynn, Olivier Lidove, Kathy Nicholls, et al.. (2022). Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?. Orphanet Journal of Rare Diseases. 17(1). 42–42. 7 indexed citations
5.
OGASAWARA, K., Mark Thomas, Liangang Liu, et al.. (2021). Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants. Cancer Chemotherapy and Pharmacology. 88(3). 369–377. 8 indexed citations
6.
OGASAWARA, K., Mark Thomas, Michael A. Thomas, et al.. (2021). Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach. Cancer Chemotherapy and Pharmacology. 88(6). 941–952. 13 indexed citations
7.
Jahan, Sadia, et al.. (2020). Prevalence of Fabry disease in dialysis patients: Western Australia Fabry disease screening study - the FoRWARD study. Orphanet Journal of Rare Diseases. 15(1). 10–10. 13 indexed citations
8.
Ekinci, Elif I., Elizabeth Barr, Federica Barzi, et al.. (2019). Is hyperfiltration associated with higher urine albumin-to-creatinine ratio at follow up among Indigenous Australians? The eGFR follow-up study. Journal of Diabetes and its Complications. 33(5). 343–349. 7 indexed citations
9.
Penm, Jonathan, et al.. (2018). The impact of using an intravenous workflow management system (IVWMS) on cost and patient safety. International Journal of Medical Informatics. 115. 73–79. 10 indexed citations
10.
McCallum, Dugald, et al.. (2015). Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma. Journal of Clinical Pathology. 68(8). 657–660. 13 indexed citations
11.
Knight, John, et al.. (2015). IgA Rheumatoid Factor and Other Autoantibodies in Acute Henoch-Sch�nlein Purpura. Contributions to nephrology. 67. 117–120.
12.
Howard, Richard F., et al.. (2010). Nurse‐controlled analgesia (NCA) following major surgery in 10 000 patients in a children’s hospital. Pediatric Anesthesia. 20(2). 126–134. 57 indexed citations
13.
Thomas, Mark, Andrew Weekes, & Merlin C. Thomas. (2007). The management of diabetes in indigenous Australians from primary care. BMC Public Health. 7(1). 303–303. 19 indexed citations
14.
Thomas, Mark. (2005). Deprivation and dialysis: Pathways to kidney failure in Australian Aborigines. Advances in Chronic Kidney Disease. 12(1). 84–87. 10 indexed citations
15.
Harris, Kevin, Mark Thomas, Colin D. Short, & Richard H. Moore. (2003). Assessment of the efficiency of treatment of dyslipidaemia in renal outpatients.. PubMed. 15(3). 263–9. 15 indexed citations
16.
Watts, Gerald F., S. Herrmann, Gursharan Dogra, et al.. (2001). Vascular function of the peripheral circulation in patients with nephrosis. Kidney International. 60(1). 182–189. 36 indexed citations
17.
Brameld, Kate, Mark Thomas, C. D’Arcy J. Holman, A. Bass, & Ian Rouse. (1999). Validation of linked administrative data on end-stage renal failure: application of record linkage to a ‘clinical base population’. Australian and New Zealand Journal of Public Health. 23(5). 464–467. 60 indexed citations
18.
Brameld, Kate, et al.. (1999). Use of a state data bank to measure incidence and prevalence of a chronic disease: End-stage renal failure. American Journal of Kidney Diseases. 34(6). 1033–1039. 12 indexed citations
19.
20.
Thomas, Mark, et al.. (1984). The perioperative management of the patient with pemphigus vulgaris and villous adenoma.. PubMed. 34(2). 180–2. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mohammad Kamgar Breakdown of academic impact, for papers by Sônia K. Nishida Breakdown of academic impact, for papers by Max Plischke Breakdown of academic impact, for papers by Miyeun Han Breakdown of academic impact, for papers by Maria Faria Breakdown of academic impact, for papers by Taner Baştürk Breakdown of academic impact, for papers by David Tovbin Breakdown of academic impact, for papers by Mustafa Sevinç Breakdown of academic impact, for papers by Elbis Ahbap Breakdown of academic impact, for papers by Rajni Sharma
Rankless by CCL
2026